Track topics on Twitter Track topics that are important to you
On August 30, 2019 VentriFlo, Inc. filed its SEC Form D, closing a $10 million Series A round toward the continued development and FDA 510(k) submission for its patented VentriFlo® blood pumping platform.
PELHAM, N.H. (PRWEB) September 19, 2019
On August 30, VentriFlo, Inc. filed its SEC Form D, closing a $10 million Series A round financed by Jim and Pat Poitras and other investors for the continued development and FDA 510(k) submission of its patented VentriFlo® blood pumping platform.
VentriFlo, Inc. originated from Design Mentor, Inc., a NH corporation with a successful history of medical device design and development, specializing in fluid pumping. Teamed with pioneering scientific and clinical advisors, VentriFlo, Inc. is dedicated to improving the outcomes of patients through innovation in blood flow.
The VentriFlo® True Pulse Pump™ is the only technology capable of replicating the native heartbeat by delivering blood flow with a life-like pulse during surgery or in the ICU. VentriFlo pumps are poised to provide better perfusion, improved patient outcomes, and reduced cost of care compared with current-use technology.
“All of our biology is based on pulsatile flow. During heart surgery, a patient’s heart is stopped, and a machine takes over the job of blood circulation”, says Doug Vincent, President & CEO of VentriFlo, Inc. He continues, “Each year a half million patients have a heart-lung machine circulating their blood during surgery and will be without a pulse for 2 hours or longer… and half of those patients suffer some form of damage to their kidneys, lungs, brain, or gut. By delivering blood flow like a natural heartbeat, VentriFlo stands to improve patient outcomes by reducing organ damage, thereby saving lives and money.”
In fact, over $6 billion annually is spent treating complications following open-heart surgery. These unreimbursed costs add significant burden to the healthcare system. The promise of VentriFlo is to reduce these costs by up to 50%.
Discussions are underway with Series B investors and multiple potential strategic partners to support post-clearance clinical and sales activities.
VentriFlo True Pulse Pumps are under development, for investigational use only, and are not available for commercial sale. VentriFlo and the VentriFlo logo are registered trademarks of VentriFlo, Inc. True Pulse Pump is a trademark of VentriFlo, Inc. VentriFlo technology is protected by US and foreign patents, including US 7,238,165 and 7,850,593 with other patents issued and pending, see http://ventriflo.com/patents/.
For the original version on PRWeb visit: https://www.prweb.com/releases/ventriflo_inc_announces_series_a_funding/prweb16568095.htmNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...